Pirfenidone 267 MG [Esbriet]
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Overview
Pirfenidone 267 MG [Esbriet] is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
Pirfenidone 267 MG [Esbriet] clinical trials
Explore related
Medical disclaimer. This page summarizes research about Pirfenidone 267 MG [Esbriet] for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.